Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387829 · ClinicalTrials.gov registry record · NA
DuraGen Plus® Adhesion Barrier for Use in Spinal Surgery
A NA study, sponsored by Integra LifeSciences Corporation.
- Terminated
- Registry status
- NA
- Development phase
- 347
- Enrollment target
NCT00387829 is a NA study that was terminated before completion, run by Integra LifeSciences Corporation. The registered enrollment target is 347 participants.
The verdict
NCT00387829, a NA study, was terminated before completion, sponsored by Integra LifeSciences Corporation.
- TERMINATED
- Registry status
- NA
- Development phase
- 347 participants
- Enrollment target
Study Summary
To evaluate the safety and effectiveness of DuraGen Plus® Adhesion Barrier Matrix as an adhesion barrier in spinal surgery to reduce the extent of peridural fibrosis formation and radicular pain in comparison to a control group receiving standard care.
Interventions
- DEVICE DuraGen Plus Adhesion Barrier Matrix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 347 participants |
| Start Date | 2006-10 |
| Est. Completion | 2011-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00387829
The ClinicalTrials.gov registry entry for NCT00387829 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 347 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Integra LifeSciences Corporation, which has 60 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DuraGen Plus Adhesion Barrier Matrix is the first listed.
NCT00387829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00387829 about?
NCT00387829 is a clinical study titled "DuraGen Plus® Adhesion Barrier for Use in Spinal Surgery". To evaluate the safety and effectiveness of DuraGen Plus® Adhesion Barrier Matrix as an adhesion barrier in spinal surgery to reduce the extent of peridural fibrosis formation and radicular pain in comparison to a control group receiving standard care.
What is the current status of trial NCT00387829?
This trial is currently terminated. It is a NA study. The enrollment target is 347 participants. The study started on 2006-10. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00387829?
The interventions under investigation include: DuraGen Plus Adhesion Barrier Matrix (DEVICE).
Who is sponsoring clinical trial NCT00387829?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.